Webinar: learn more about a new treatment option for recurrent pericarditis

Join Us!

UPCOMING WEBINAR: April 28, 2021
7:00 PM EST

Introducing ARCALYST (rilonacept) - The first and only FDA-approved therapy that treats recurrent pericarditis and reduces the risk of future flares

About Webinar

Join Dr. Martin LeWinter, Cardiologist at University of Vermont Medical Center, to learn about a new treatment option for recurrent pericarditis.

April Scott, Senior Director of Patient Services at Kiniksa Pharmaceuticals will introduce Kiniksa One Connect, a patient support program designed to provide you with personalized support through your treatment journey.

During this educational webinar you will learn about:

Recurrent pericarditis
Treatment with ARCALYST
Support services offered by Kiniksa One Connect

If you have a question or a topic that you would like us to cover in our webinar series, please make sure to submit it when you register!

Speakers

LeWinter

Dr. Martin LeWinter
Cardiologist at University of Vermont Medical Center

Dana Martin

Dana Martin, PharmD
Senior Vice President of Global Medical Affairs and Patient Advocacy at Kiniksa Pharmaceuticals

April Scott

April Scott
Senior Director of Patient Services at Kiniksa Pharmaceuticals

Contact Us

Important Safety Information

ARCALYST can affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death have happened in patients taking ARCALYST. You should not begin ARCALYST if you have an infection, or have infections that keep coming back. After starting ARCALYST, if you get an infection or show any sign of an infection, including a fever, cough, flu-like symptoms, or have any open sores on your body, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection.
While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel® (etanercept), Humira® (adalimumab), or Remicade® (infliximab), as this may increase your risk of getting a serious infection.
Before starting ARCALYST, tell your doctor if you think you have an infection, are being treated for an infection, have signs of an infection, have any open sores, have a history of infections that keep coming back, have asthma, have diabetes or an immune system problem, have tuberculosis or have been in contact with someone who has had tuberculosis, have or have had HIV, hepatitis B or hepatitis C, or take other medicines that affect your immune system.
Before you begin treatment with ARCALYST, talk with your healthcare provider about your vaccine history. Ask your healthcare provider whether you should receive any vaccines, including the pneumonia vaccine and flu vaccine, before you begin treatment with ARCALYST.
ARCALYST can cause serious side effects:
- Medicines that affect the immune system may increase the risk of getting cancer.
- Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction (eg, rash, swollen face, trouble breathing).
- Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.
Common side effects of ARCALYST include injection-site reactions, upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose.
Tell your doctor if you are scheduled to receive any vaccines, if you are pregnant or plan to become pregnant, and if you are breastfeeding or plan to breastfeed.
Tell your doctor if you take other medicines that affect the immune system such as interleukin-1 blockers, tumor necrosis factor blockers, or corticosteroids.

For more information about ARCALYST, talk to your doctor and see the Product Information.

INDICATION

ARCALYST® (rilonacept) is an interleukin-1 blocker indicated for:

Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older.
Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older.
Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more.

Go Back Continue